Skip to Main Content

Paper Details

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
J Acquir Immune Defic Syndr
16
2021
CD4-binding site, HIV, HIV envelope protein, HIV-1, HPTN 085, HVTN 704, Participants, VRC01, individuals, men, participant, participants, person, sexually transmitted infection, women
Author NameAffiliation
Ian FrankUniversity of Pennsylvania
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • 1 - 2

Datasets

Release 1.2